Full Press Release Details
THERAPEUTICS LIMITED ("the Company")
THERAPEUTICS LIMITED
GENERAL MEETING - NOTICE AND PROXY FORM
ANNUAL GENERAL MEETING
Company's annual general meeting is scheduled to be held at the offices of Deloitte Australia, Level 30, 477 Collins Street, Melbourne,
VIC 3000 on Friday, 21 November 2025 at 11:00am (AEDT) (Meeting).
accordance with new provisions under the Corporations Act, the Company will not be sending hard copies of the Notice of Meeting to shareholders
unless a shareholder has previously requested a hard copy. The Notice of Meeting can be viewed and downloaded at https://alteritytherapeutics.com/investor-overview/asx-announcements.
Company strongly encourages Shareholders to lodge a directed proxy form prior to the meeting. Questions should also be submitted
in advance of the Meeting as this will provide management with the best opportunity to prepare for the Meeting, for example by preparing
answers in advance to Shareholders questions. However, votes and questions may also be submitted during the Meeting. Further details
of how to participate in the Meeting are set out in the Online Meeting Guide.
find links to important Meeting documents: Notice of Meeting and Explanatory Memorandum: https://alteritytherapeutics.com/investor-overview/asx-announcements.
you have nominated an email address and have elected to receive electronic communications from the Company, you will also receive an
email to your nominated email address with a link to an electronic copy of the important Meeting documents.
you are unable to access any of the important Meeting documents online, please contact the Company Secretary, Abby Macnish Niven, via
email at cfo@alteritytx.com.
Company will notify Shareholders via the Company's website at www.alteritytherapeutics.com and the Company's ASX Announcement
Platform at asx.com.au (ASX:ATH) if changing circumstances impact the planning or arrangements for the Meeting.
announcement is authorised for market release by the Board of Alterity Therapeutics Limited.
Therapeutics Limited
MEETING AND EXPLANATORY
| Date of Meeting: | Friday, 21 November 2025 | |
| Time of Meeting: | 11:00am (Melbourne time) | |
| Place of Meeting: | Deloitte Australia Offices, Level 30, 477 Collins Street, | |
| Melbourne VIC 3000 |
Proxy Form is enclosed or has otherwise been provided to you
read this Notice and Explanatory Memorandum carefully.
you are unable to attend the Annual General Meeting you are encouraged to appoint a proxy to vote on your behalf.
Therapeutics Limited
of Annual General Meeting
is given that the Annual General Meeting of Shareholders of Alterity Therapeutics Limited ABN 37 080 699 065 will be held at Deloitte
Australia Offices, Level 30, 477 Collins Street, Melbourne VIC 3000 on Friday, 21 November 2025 at 11:00am (Melbourne time) for the purpose
of transacting the following business referred to in this Notice of Annual General Meeting.
receive and consider the financial report of the Company for the year ended 30 June 2025, together with the Directors' Report and
the Auditor's Report as set out in the Annual Report.
consider and, if thought fit, pass the following resolution as a non-binding resolution:
the Remuneration Report for the year ended 30 June 2025 as set out in the Annual Report be adopted."
The vote on this Resolution is advisory only and does not bind the Directors or the Company. Shareholders are encouraged to read the
Explanatory Memorandum for further details on the consequences of voting on this Resolution.
exclusion statement: The Company will disregard any votes cast on the Resolution by or on behalf of a member of the Key Management
Personnel whose remuneration details are included in the Remuneration Report, or their Closely Related Parties. However, the Company
need not disregard a vote if:
a Restricted Voter who is appointed as a proxy will not vote on the Resolution unless:
may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
any of the persons named above purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as
indicated above) and those persons may be liable for breaching the voting restrictions that apply to them under the Corporations Act.
consider and, if thought fit, to pass the following resolution as an ordinary resolution:
Mr Brian Meltzer, who retires in accordance with clauses 20.1 and 20.2 of the Constitution, Listing Rule 14.4, and Listing Rule 14.5
and, being eligible for re-election, be re- elected as a Director."
consider and, if thought fit to pass the following resolution as an ordinary resolution:
for the purpose of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 920,874,966 Placement Shares (at an
issue price of $0.012 each) on 15 September 2025 to institutional and sophisticated investors under the Placement on the terms and conditions
set out in the Explanatory Memorandum."
exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
this does not apply to a vote cast in favour of the Resolution by:
consider and, if thought fit to pass the following resolution as an ordinary resolution:
for the purpose of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 745,791,697 Placement Shares (at an
issue price of $0.012 each) on 15 September 2025 to institutional and sophisticated investors under the Placement on the terms and conditions
set out in the Explanatory Memorandum."
exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
this does not apply to a vote cast in favour of the Resolution by:
consider and, if thought fit, to pass the following resolution as an ordinary resolution:
for the purposes of Listing Rule 7.2 Exception 13(b) and for all other purposes, Shareholders approve the issue of Incentives under the
2004 ASX Plan on the terms and conditions described in the Explanatory Memorandum."
exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
this does not apply to a vote cast in favour of the Resolution by:
a Restricted Voter who is appointed as a proxy will not vote on the Resolution unless:
may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
any of the persons named above purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as
indicated above) and those persons may be liable for breaching the voting restrictions that apply to them under the Corporations Act.
consider and, if thought fit, to pass the following resolution as an ordinary resolution:
for the purposes of Listing Rule 7.2 Exception 13(b) and for all other purposes, Shareholders approve the issue of Incentives under the
2018 ADS Plan on the terms and conditions described in the Explanatory Memorandum."
exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
this does not apply to a vote cast in favour of the Resolution by:
a Restricted Voter who is appointed as a proxy will not vote on the Resolution unless:
may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
any of the persons named above purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as
indicated above) and those persons may be liable for breaching the voting restrictions that apply to them under the Corporations Act.
consider and, if thought fit, to pass the following resolution as a special resolution:
for the purpose of Listing Rule 7.1A and all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the issued
capital of the Company (at the time of the issue) calculated in accordance with Listing Rule 7.1A.2 and on the terms and conditions set
out in the Explanatory Memorandum."
voting exclusion statement is included for this Resolution because the Company is not proposing any issue of Equity Securities under
Listing Rule 7.1A as at the date of this Notice.
consider and, if thought fit, to pass the following resolution as a special resolution:
the Constitution contained in the document submitted to this Meeting and signed by the Chair for identification purposes be approved
and adopted as the Constitution of the Company in substitution for the existing Constitution of the Company with effect from the end
consider and, if thought fit, to pass the following resolution as a special resolution:
subject to and conditional on Resolution 8 not being approved, for the purposes of section 648G of the Corporations Act and for all other
purposes, the Constitution of the Company be amended, with immediate effect, in the manner outlined in the Explanatory Memorandum to
this Notice of Meeting and set out in Annexure C to the Explanatory Memorandum, to include a requirement for Shareholder approval of
any proportional takeover bids, as permitted under the Corporations Act."
deal with any other business which may be brought forward in accordance with the Constitution and the Corporations Act.
of the definitions and abbreviations used in this Notice are set out in the Glossary to the Explanatory Memorandum.
By order of the Board
resolution, other than a procedural resolution which shall include the election of a Chair, put to the vote of the Meeting will be decided
by a poll in accordance with the Corporations Act unless otherwise determined by the Chair.
the case of joint holders of Shares, if more than one holder votes at the Meeting, only the vote of the first named of the joint holders
in the share register of the Company will be counted.
in person (or by attorney)
or their attorneys, who plan to attend the Meeting are asked to arrive at the venue 15 minutes prior to the time designated for the Meeting,